A Study To Assess The Effect Of Pyridoxine Supplementation In Preventing Migraine Attacks
Phase 4
- Conditions
- Health Condition 1: null- MigraineHealth Condition 2: G43- Migraine
- Registration Number
- CTRI/2018/07/014731
- Lead Sponsor
- Dr N Caroline devakirubai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed as chronic migraine and on regular prophylaxis 6months or more
Patients willing to give a written informed consent
Exclusion Criteria
Patients with headache other than migraine
Patients with peripheral neuropathy or photosensitivity
Patients with major systemic illness
Patients taking vitamin supplements
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method reduction of MIDAS scoreTimepoint: 9 Months
- Secondary Outcome Measures
Name Time Method The tolerability of the study drug will be assessed in migraine patients clinicallyTimepoint: tolerability of the intervention drug pyridoxine for the period of 6 months and 3 months follow up